EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force

Pablo Rodríguez Del Río iD, Montserrat Álvaro-Lozano iD, Stefania Arasi iD, Raphaëlle Bazire iD, Carmelo Escudero iD, Nandinee Patel iD, Monica Sandoval-Ruballos iD, Marta Vazquez-Ortiz iD, Anna Nowak-Wegrzyn iD, Katharina Blümchen iD, Audrey Dunn Galvin iD, Antoine Deschildre iD und 6 weitere

Allergy · 2024-04 · 79 (4) · 793-822

DOI: 10.1111/all.16027 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 23.01.2024. Verfasst von Pablo Rodríguez Del Río und 17 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Food Hypersensitivity, Allergens. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 115 Literaturangaben. Gefördert von: Medical Research Council, European Academy of Allergy and Clinical Immunology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Food allergy is a global public health problem that until recent years lacked any aetiological treatment supported by academy, industry and regulators. Food immunotherapy (AIT) is an evolving treatment option, supported by clinical practice and industry trial data. Recent AIT meta‐analyses have highlighted the difficulty in pooling safety and efficacy data from AIT trials, due to secondary heterogeneity in the study. An EAACI task force (CO‐FAITH) initiated by the Paediatric Section was created to focus on AIT efficacy outcomes for milk, egg and peanut allergy rather than in trial results. A systematic search and a narrative review of AIT controlled clinical trials and large case series was conducted. A total of 63 manuscripts met inclusion criteria, corresponding to 23, 21 and 22 studies of milk, egg and peanut AIT, respectively. The most common AIT efficacy outcome was desensitization, mostly defined as tolerating a maintenance phase dose, or reaching a particular dose upon successful exit oral food challenge (OFC). However, a large degree of heterogeneity was identified regarding the dose quantity defining this outcome. Sustained unresponsiveness and patient‐reported outcomes (e.g. quality of life) were explored less frequently, and to date have been most rigorously described for peanut AIT versus other allergens. Change in allergen threshold assessed by OFC remains the most common efficacy measure, but OFC methods suffer from heterogeneity and methodological disparity. This review has identified multiple heterogeneous outcomes related to measuring the efficacy of AIT. Efforts to better standardize and harmonize which outcomes, and how to measure them must be carried out to help in the clinical development of safe and efficacious food allergy treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicFood HypersensitivityAllergensHumansTreatment OutcomeClinical Trials as TopicAdvisory Committees

Stichwörter der Autor:innen

allergy treatmentepicutaneous immunotherapyfood allergyfood immunotherapyoral immunotherapysublingual immunotherapy

Substanzen

Allergens

Autor:innen und Institutionen

  • Allergy Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
  • FibHNJ, ARADyAL-RETICs RD16 /0006/0026 Instituto de Salud Carlos III, Madrid, Spain.
  • IIS La Princesa, Madrid, Spain.
  • Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain.
  • Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
  • Universitat de Barcelona, Barcelona, Spain.

ORCID-Profile: Pablo Rodríguez Del Río, Montserrat Álvaro-Lozano, Stefania Arasi, Raphaëlle Bazire, Carmelo Escudero, Nandinee Patel, Monica Sandoval-Ruballos, Marta Vazquez-Ortiz, Anna Nowak-Wegrzyn, Katharina Blümchen, Audrey Dunn Galvin, Antoine Deschildre, Matthew Greenhawt, Carmen Riggioni, Benjamin C Remington, Paul Turner, Montserrat Fernandez Rivas

Förderung

  • Medical Research Council
  • European Academy of Allergy and Clinical Immunology

Zitieren

APA

Rodríguez Del Río, P., Álvaro-Lozano, M., Arasi, S., Bazire, R., Escudero, C., Patel, N., Sandoval-Ruballos, M., Vazquez-Ortiz, M., Nowak-Wegrzyn, A., Blümchen, K., Dunn Galvin, A., Deschildre, A., Greenhawt, M., Schnadt, S., Riggioni, C., Remington, B. C., Turner, P., & Fernandez Rivas, M. (2024). Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force. Allergy, 79(4), 793-822. https://doi.org/10.1111/all.16027

Vancouver

Rodríguez Del Río P, Álvaro-Lozano M, Arasi S, Bazire R, Escudero C, Patel N, et al. Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force. Allergy. 2024;79(4):793-822. doi:10.1111/all.16027

BibTeX
@article{RodrguezDelRo2024,
  author = {Rodríguez Del Río, Pablo and Álvaro-Lozano, Montserrat and Arasi, Stefania and Bazire, Raphaëlle and Escudero, Carmelo and Patel, Nandinee and Sandoval-Ruballos, Monica and Vazquez-Ortiz, Marta and Nowak-Wegrzyn, Anna and Blümchen, Katharina and Dunn Galvin, Audrey and Deschildre, Antoine and Greenhawt, Matthew and Schnadt, Sabine and Riggioni, Carmen and Remington, Benjamin C and Turner, Paul and Fernandez Rivas, Montserrat},
  title = {Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {4},
  pages = {793--822},
  doi = {10.1111/all.16027}
}
Kostenlos starten →